Related Experiment Video
Updated: May 3, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
[Medicinal rate control in atrial fibrillation]
1Medizinische Klinik I, Ludwig-Maximilians-Universität, Marchioninistr. 15, 81377, München, Deutschland, michael.nabauer@med.uni-muenchen.de.
Abstract:
Atrial fibrillation is the most common form of persistent arrhythmia. Atrial fibrillation frequently causes rapid ventricular response with severe clinical symptoms requiring acute control of the ventricular rate. This leads to hemodynamic stabilization and improvement of symptoms. The long-term treatment target is to minimize patient symptoms and prevention of complications. As a rhythm control strategy does not provide a survival benefit compared to a rate control strategy, decisions on the best long-term treatment have to be individualized. Important factors affecting this decision are age of the patient, chances to re-establish and maintain sinus rhythm, tolerance of antiarrhythmic medication and accompanying diseases of the heart. For younger patients a rhythm control strategy will usually be the preferred option. For rate control beta blockers are considered first line therapy, alternative drugs include calcium antagonists and digoxin. Occasionally, amiodarone may also be used for rate control. If pharmacological rate management fails ablation of the atrioventricular (AV) node may be an option to control the ventricular rate.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Mitral Regurgitation III: Medical Management

